ArticleScientific reports2026
Generating explainable hypotheses for drug repurposing with graph neural networks.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Biomedical knowledge discovery increasingly relies on computational tools to uncover patterns in complex datasets, yet generating explainable, evidence-based hypotheses about biological interactions remains challenging. This study introduces XAIPath, an interpretable pipeline that leverages biomedical knowledge graphs and Graph Neural Networks (GNNs) to uncover and explain novel drug-disease relationships, aiding applications such as drug repurposing. The pipeline combines GNN-based predictions with a post-hoc interpretability layer that extracts simple paths connecting drug and disease nodes in a biomedical knowledge graph and compares them using MinHash-based similarity. Similar paths are grouped via K-means clustering to build interpretable clusters that represent alternative mechanistic hypotheses. The method was applied to the NeDRex knowledge graph for drug indication prediction, with performance evaluated using AUROC, AUPRC, precision, sensitivity, and specificity. XAIPath achieved strong predictive performance, with AUROC exceeding 95% and AUPRC over 90% across training, validation, and test sets, while precision, sensitivity, and specificity all surpassed 85%. Most high-scoring predictions were supported by existing literature, and the extracted path clusters closely aligned with DrugMechDB annotations, supporting the plausibility of the generated hypotheses. Overall, XAIPath offers a scalable and explainable approach for identifying drug-disease associations, facilitating hypothesis generation and biological validation, and highlighting the value of explainable AI in biomedical research and drug repurposing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.